GLP-1 drugs like Ozempic and Wegovy have reshaped how we treat obesity and diabetes — but what’s on the horizon? In this final episode of Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons explore the future of these groundbreaking medications through insights from top experts. Dr. William Hsu discusses the possibility of diabetes remission without lifelong medications. Dr. Elizabeth Van Dril sees GLP-1s becoming standard care, while Dr. Ashley Dwyer warns about disordered eating habits. Dr. Lauren Cunningham emphasizes the importance of metabolic health over numbers on a scale. Rob Andrews explains how Medicare must adopt value-based pricing to ensure cost-effective access. And Dr. Steve Boyd warns that, unless we fix the healthcare system, the GLP-1 surge may not be sustainable. Whether you’re taking these drugs, considering them, or just following the conversation, this episode offers essential insights into what lies ahead. Learn more at Drugwatch.com.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
Buchladen: Tipps für Weihnachten
20 Dec 2025
eat.READ.sleep. Bücher für dich
BOJ alza 25pb decennale sopra 2%, Oracle vola con accordo Tik Tok, 90 mld eurobond per Ucraina | Morning Finance
19 Dec 2025
Black Box - La scatola nera della finanza
365. The BEST advice for managing ADHD in your 20s ft. Chris Wang
19 Dec 2025
The Psychology of your 20s
LVST 19 de diciembre de 2025
19 Dec 2025
La Venganza Será Terrible (oficial)
Cuando la Ciencia Ficción Explicó el Mundo que Hoy Vivimos
19 Dec 2025
El Podcast de Marc Vidal